ArticlebioRxiv : the preprint server for biology2025
Plasma Proteomic Profiling Reveals Distinct Signatures of Chest CT Phenotypes in Sarcoidosis.
Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Background: Sarcoidosis is a granulomatous disease of unknown cause with a highly variable clinical course. The inability to predict progressive inflammation, fibrosis, or both underscores the limited understanding of the underlying molecular mechanisms. Objective: We aimed to identify novel protein signatures associated with distinct pulmonary phenotypes of sarcoidosis, including progressive inflammation, progressive fibrosis, and disease resolution. Methods: We performed the SomaScan 11K Assay to measure more than 10,000 unique human plasma proteins and compared protein expression between chest CT-defined phenotypes using principal component analysis, differential expression, correlation analysis, and gene set enrichment analysis. Results: We identified distinct proteomic signatures that differentiate progressive fibrosis from progressive nodular inflammation in sarcoidosis. Enrichment and differential expression analyses revealed that progressive fibrosis was associated with epithelial-mesenchymal transition pathways, while progressive nodular disease was linked to mTORC1 and MYC signaling, as well as metabolic activation. Additionally, expression of 44 proteins correlated moderately to strongly with thoracic lymph node enlargement, suggesting that lymph node-driven immune activity may be a major source of circulating proteomic signals. Conclusions: This study leverages a unique longitudinal imaging approach to define extreme pulmonary phenotypes based on serial chest CT scoring, enabling the discovery of proteomic signals linked to distinct trajectories of sarcoidosis progression. Once validated, these findings could inform the development of blood-based biomarkers for disease stratification, monitoring, and therapeutic targeting in sarcoidosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.